Breaking News, Collaborations & Alliances

Evotec, Shionogi Enter Drug Discovery Pact

Evotec AG and Shionogi & Co Ltd. have entered a fragment-based drug discovery alliance to identify small molecule modulators of various protein-protein interaction targets selected by Shionogi.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Evotec AG and Shionogi & Co Ltd. have entered a fragment-based drug discovery alliance to identify small molecule modulators of various protein-protein interaction targets selected by Shionogi. Evotec will apply its integrated fragment-based drug discovery platform, EVOlution. The platform, used for the selection of target-specific strategies, combines biochemical and biophysical techniques including nuclear magnetic resonance
(NMR), surface plasmon resonance (SPR) and X-ray crystallography....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters